SEC Company Response from Voyager Therapeutics, Inc. (VYGR) (CIK 0001640266) (VYGR) — Nov 10, 2022

Voyager Therapeutics, Inc. (VYGR) (CIK 0001640266)
Date: Nov. 10, 2022 · CIK: 0001640266 · Accession: 0001104659-22-117121

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-268240

Date

November 10, 2022

Author

Peter P. Pfreundschuh

Form

CORRESP

Company

Voyager Therapeutics, Inc. (VYGR) (CIK 0001640266)

Letter

VOYAGER THERAPEUTICS, INC.

64 Sidney Street

Cambridge, MA 02139

November 10, 2022

VIA EDGAR SUBMISSION

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Voyager Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-268240 Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Voyager Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-268240), so that it may become effective at 4:30 p.m., Eastern time, on November 15, 2022, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

Very truly yours,
VOYAGER THERAPEUTICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

VOYAGER THERAPEUTICS, INC.

64 Sidney Street

Cambridge, MA 02139

November 10, 2022

VIA EDGAR SUBMISSION

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Voyager Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-268240
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933,
as amended, Voyager Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of
its Registration Statement on Form S-3 (File No. 333-268240), so that it may become effective at 4:30 p.m., Eastern time,
on November 15, 2022, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request
via telephone call to the staff.

    Very truly yours,

    VOYAGER THERAPEUTICS, INC.

    By:
    /s/ Peter P. Pfreundschuh

    Name:
    Peter P. Pfreundschuh

    Title:
    Chief Financial Officer

    cc:
    Robert W. Hesslein

    Senior Vice President and General Counsel

    Voyager Therapeutics, Inc.

    Brian A. Johnson

    C.S. Avery Reaves

    Wilmer Cutler Pickering Hale
    and Dorr LLP

SecProbe.io